Semorinemab Drug Asset Due Diligence Report 2026

This Semorinemab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Semorinemab can convert its Monoclonal antibody profile and TAU biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Semorinemab (query alias: Semorinemab)
Modality / target	Monoclonal antibody; TAU; TAU inhibitors
Highest global status	Discontinued
Originator	AC Immune SA
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03289143	Phase 2	Terminated	457	Change From Baseline on the CDR-SB
NCT03828747	Phase 2	Completed	272	Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-Item Version (ADAS-Cog11)
NCT02820896	Phase 1	Completed	74	Number of Participants with Adverse Events

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

P079- PHARMACODYNAMIC EFFECTS OF SEMORINEMAB ON BIOMARKERS OF TAU, SYNAPTIC FUNCTION, AND GLIOSIS IN A PHASE 2 TRIAL OF MILD-TO-MODERATE ALZHEIMER'S DISEASE (LAURIET)

Phase 2; n=272; evaluation: Positive. Reported fields: CSF total tau(annualized reductions) = 1.0 % ; -

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

Phase 2; n=238; evaluation: Negative. Reported fields: ADAS-Cog: P-Value = 0.0008; ADAS-Cog = -2.89 points ( -4.56 to -1.21)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease

Phase 2; n=272; evaluation: not stated. Reported fields: Baseline(Least Squares Mean) = 24.09 Units on a scale (Standard Error, 0.589); -; Baseline(Least Squares Mean) = 23.93 Units on a scale (Standard Error, 0.533)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Semorinemab addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-01-22	AC Immune To Regain Global Rights To Crenezumab And Semorinemab	Preclinical	US$419.0M stated total
2015-01-12	AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer’s Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.	Phase 1	US$509.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating TAU pathologies”. The milestone feed surfaced a patent-application signal described as “Uses of TAU phosphosites as biomarkers for alzheimer's disease”. The milestone feed surfaced a patent-application signal described as “Determination agent and determination method for tauopathy and dementia-related diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION